Genprex receives patent allowances for cancer therapy combinations

AUSTIN, Texas - Genprex, Inc. (NASDAQ:GNPX), a clinical-stage gene therapy company with a market capitalization of $7 million, announced Monday that it has received Notices of Allowance for patents covering its lead drug candidate REQORSA Gene Therapy in combination with immune checkpoint inhibitors. According to InvestingPro data, while the company maintains a healthy balance sheet with more cash than debt, it faces near-term liquidity challenges with a current ratio of 0.84.

The U.S. Patent and Trademark Office has allowed a patent for REQORSA in combination with PD-L1 antibodies such as Tecentriq, while the European Patent Office has allowed a patent for REQORSA in combination with PD-1 antibodies. Both patents will expire no earlier than 2037. The stock, currently trading at $0.21, has seen significant volatility with a beta of -0.52, indicating movement contrary to broader market trends. InvestingPro subscribers can access 10+ additional insights about Genprex’s market performance and financial health.

These patents strengthen Genprex’s intellectual property protection for its oncology program, particularly for applications in its ongoing Acclaim-3 clinical trial, according to the company’s press release.

"We are very proud to continue building a fortress of intellectual property protection around our oncology program for REQORSA," said Thomas Gallagher, Senior Vice President of Intellectual Property and Licensing at Genprex.

The company has already secured patents for REQORSA with PD-L1 antibodies in Korea and for REQORSA with PD-1 antibodies in multiple countries including the U.S., Japan, China, and Australia. Genprex is pursuing additional patent applications in several other countries.

The Acclaim-3 study is a Phase 1/2 clinical trial evaluating REQORSA and Tecentriq as maintenance therapy for patients with extensive stage small cell lung cancer. This trial has received both Fast Track Designation and Orphan Drug Designation from the FDA. Despite these positive developments, the company reported an EBITDA of -$17.31 million in the last twelve months, reflecting the substantial costs associated with clinical development.

Genprex is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. Its oncology program uses a non-viral delivery system to administer gene-expressing plasmids to tumor cells.

In other recent news, Genprex, Inc. has announced its compliance with the Nasdaq Capital Market’s minimum stockholders’ equity requirement. This compliance was confirmed by Nasdaq’s Listing Qualifications Department, resolving an issue that began in November 2024 when the company’s equity fell below the required $2.5 million. Genprex addressed this deficiency through its financial results for the quarter ending March 31, 2025. Additionally, Genprex reported positive results from a diabetes gene therapy study. The study, presented at the American Diabetes Association’s 85th Scientific Sessions, showed that their diabetes gene therapy candidate, GPX-002, improved glucose control in animal models of Type 1 diabetes for three months. These developments highlight Genprex’s ongoing efforts in both financial stability and innovative research.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.